MENS
Jyong Biotech Ltd. (NASDAQ)
Healthcare — Biotechnology
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
None
$2.05
$-0.02 (-0.97%)
Sign in to add MENS to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $155.86M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.06 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 66.0 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $67.00 |
| 52-Week Low | $1.43 |
| 50-Day Avg | $2.01 |
| 200-Day Avg | $16.03 |
| Avg Volume | 103.0K |
| Volume | 55.8K |
Performance Analysis
BULLISHMENS shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($1.43), which could present a value opportunity.
+
RSI at 66.0 shows positive momentum.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:19 UTC
Back to Screener Export Report